Basilea Pharmaceutica
€59.1
17
+€1.2+2.07% Today
Statistics
Day High
59.1
Day Low
59.1
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Dividends
0%Dividend Yield
Jun 13
€4.1
Jun 13
€5
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A
Earnings
17FebExpected
Expected EPS
1.590163835474928
Actual EPS
1.499666603950032
Financials
20.71%Profit Margin
Profitable417.16MRevenue
86.38MNet Income
People Also Follow
This list is based on the watchlists of people on Stock Events who follow PK5.F. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap300.2B
Pfizer
PFE
Mkt Cap153.13B
Astrazeneca
AZN
Mkt Cap316.3B
Gilead Sciences
GILD
Mkt Cap172.51B
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Novartis
NVS
Mkt Cap297.35B
Roche
RHHBY
Mkt Cap322.3B
Abbvie
ABBV
Mkt Cap367.8B
AMGEN
AMGN
Mkt Cap189.22B
Johnson & Johnson
JNJ
Mkt Cap574.66B
About
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.
Show more...
CEO
Mr. David Veitch
Employees
154
Country
Switzerland
ISIN
CH0011432447
WKN
000A0B9GA
Listings
0 Comments
Share your thoughts
FAQ
What is Basilea Pharmaceutica stock price today?▼
The current price of PK5.F is €59.1 EUR — it has increased by +2.07% in the past 24 hours. Watch Basilea Pharmaceutica stock price performance more closely on the chart.
What is Basilea Pharmaceutica stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Basilea Pharmaceutica stocks are traded under the ticker PK5.F.
When is the next Basilea Pharmaceutica earnings date?▼
Basilea Pharmaceutica is going to release the next earnings report on August 18, 2026.
What were Basilea Pharmaceutica earnings last quarter?▼
PK5.F earnings for the last quarter are 1.64 EUR per share, whereas the estimation was 1.74 EUR resulting in a -5.69% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Basilea Pharmaceutica revenue for the last year?▼
Basilea Pharmaceutica revenue for the last year amounts to 417.16M EUR.
What is Basilea Pharmaceutica net income for the last year?▼
PK5.F net income for the last year is 86.38M EUR.
Does Basilea Pharmaceutica pay dividends?▼
Yes, PK5.F dividends are paid en. The last dividend per share was 4.1 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Basilea Pharmaceutica have?▼
As of April 14, 2026, the company has 154 employees.
In which sector is Basilea Pharmaceutica located?▼
Basilea Pharmaceutica operates in the Health & Wellness sector.
When did Basilea Pharmaceutica complete a stock split?▼
Basilea Pharmaceutica has not had any recent stock splits.
Where is Basilea Pharmaceutica headquartered?▼
Basilea Pharmaceutica is headquartered in Basel, Switzerland.